Health Professionals

A close up shot of a green stethoscope on top of a doctor's notes

Liver disease may be silent, but it is on the rise.

1 in 4 Canadians – men, women and children – may be affected by liver disease. As a healthcare professional, you want access to reliable information and resources to help you and your patients. The Canadian Liver Foundation partners with professional associations like the Canadian Association for the Study of the Liver (CASL), academic and research institutions, hospitals, government agencies and others to assist in the provision of evidence-based information and practical tools and resources to help you improve liver health in your community through prevention, diagnosis, treatment and care.

Your experience matters!

If you have liver cancer (hepatocellular carcinoma) that cannot be removed with surgery (unresectable) or are caring for someone who has it, we would like to hear from you. The Canadian Liver Foundation (CLF) is seeking patient, caregiver and health professional input to include in our submission to Health Canada in regard to regorafenib (Stivarga). We invite you to be part of it by sharing your comments and personal experiences, completing this survey in English, French or Chinese.


Note
:
The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

Risk Factors

Diagnostics

Clinical Practice Guidelines

Resources

Meetings & Conferences


Risk Factors

Liver disease can often be difficult to diagnose because its symptoms can be vague and easily confused with other health problems. In some cases, a person may have no symptoms at all and yet the liver may already have suffered significant damage. Risk factors can vary significantly across the 100+ forms of liver disease, so there is not one single “profile” of a patient who may have liver disease – it can affect anyone, at any age, of any socio-economic status and of any ethnic background.

It is important for healthcare professionals to be aware of some of the more common risk factors and symptoms for liver disease so you can proactively look for these warning signs and take the necessary steps (i.e.: learn more, order the appropriate tests, consult with a specialist) because early diagnosis of liver disease gives you and your patient the best chance at effectively addressing the liver disease.

Some of the more common and identifiable risk factors for liver disease may include:

  • Obesity / Diabetes (i.e.: metabolic syndrome)
  • Exposure to certain chemicals or toxins including prescription and over-the-counter medications, herbal medications and recreational “street drugs” (i.e.: acetaminophen overdose, mixing medication with alcohol)
  • Heavy alcohol consumption
  • Family history of liver disease
  • Exposure to hepatitis B or C virus in blood or bodily fluids:
    • Blood, blood products or an organ donation or transplant prior to 1990 in Canada
    • Injection or intranasal drug use or shared drug paraphernalia
    • Born in other parts of the world where hepatitis B and hepatitis C are more common (i.e.: Central, East and South Asia; Australasia and Oceania; Eastern Europe; Sub-Saharan Africa; and North Africa/Middle East)
    • Improperly sterilized equipment (dental procedures, kidney/hemodialysis treatment, tattoos & body piercings, etc.)
    • Unprotected sexual intercourse

Some of the more common and identifiable symptoms of decompensated liver disease include:

  • Jaundice (yellowing of the skin and eyes due to elevated bilirubin in the blood)
  • Nausea, vomiting or loss of appetite
  • Abdominal swelling (ascites) or tenderness in the area of the liver
  • Chronic fatigue
  • Itchy skin (pruritus)
  • Dark colour urine
  • Pale or bloody stool
  • Dementia-like confusion (hepatic encephalopathy)
Note:

The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.


Diagnostics

Diagnosis and management of liver disease begins with gathering information during your patient consultation, including patient/family history, physical examination and the administration of liver tests. This combination of information will help to guide your decisions on how to effectively recognize, respond and resolve liver health issues with your patients.

A diagram showing the makeup of a healthy liver versus a fatty liver versus a cirrhotic liver.The Canadian Liver Foundation encourages all Primary Healthcare Providers to engage in frank discussions with their patients regarding possible risk factors for liver disease, including topics such as drug use (past or current), alcohol consumption, sexual activity, diet and exercise and medication management (prescription, over-the-counter and complementary/alternative).

The CLF also recommends that all Primary Healthcare Providers incorporate liver function tests as part of the routine blood panel ordered during regular physical check-ups with your patients. These preliminary liver function tests will help to identify whether additional investigation needs to be undertaken:

Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)

The ALT and AST tests measure the amount of these enzymes in the blood. ALT and AST are found mainly in liver cells but if the liver cells are damaged, these enzymes can leak out of the liver cells and make their way into the bloodstream. Most increases in ALT and AST levels can be an indicator of liver damage but do not reflect the liver’s actual functional ability.

Alkaline phosphatase (ALP)

The ALP test measures the amount of this enzyme in the blood. ALP is produced mostly in the liver and is used most frequently to detect obstruction in the biliary system. Elevation of this enzyme may be found in a large number of liver disorders including gallstone disease, alcohol abuse, drug-induced hepatitis and primary biliary cholangitis. Increased levels of ALP can be an indicator of possible liver or bile duct damage. 

Total Bilirubin, International Normalized Ratio (INR) and Serum Albumin

These are surrogate markers of liver function and when there is significant decompensation, these lab tests will be abnormal. The degree of abnormality reflects the liver’s residual functional ability. All three laboratory markers are components of the Child-Pugh Score which is a global score of liver decompensation. The INR and bilirubin, along with the serum creatinine (a marker of kidney function that is abnormal in serious liver dysfunction) are also components in the MELD Score (Model for End-Stage Liver Disease). The MELD score is the only approved score in the United States for liver transplant waiting list assignment and triage. The MELD score, with the Child-Pugh Score, is also used by all Canadian liver transplant centres.

Additional Diagnostics Tools & Calculators

iMD Health Canada

iMD Health Canada
Purpose: Award-winning interactive touch-screen computer terminal that helps doctors communicate liver disease information more effectively to patients and their caregivers at the point of care. This system is loaded with information for both doctors and their patients including: images, understanding, lifestyle, prescription and over-the-counter medications, consumer care and professional tools.
Find more information here.

LiverTox

LiverTox
Purpose: Up-to-date, accurate, and easily accessed information on the diagnosis, cause, frequency, patterns, and management of liver injury attributable to prescription and non-prescription medications, herbals and dietary supplements.
Information and search database

Model for End-Stage Liver Disease Score (MELD Score)

Model for End-Stage Liver Disease Score (MELD Score)
Purpose: To assess the severity of liver disease and to determine prognosis and prioritize for receipt of a liver transplant.
Information and calculator

Pediatric End-Stage Liver Disease Score (PELD Score)

Pediatric End-Stage Liver Disease Score (PELD Score)
Purpose: To assess the severity of liver disease for children under 12 years of age and to determine prognosis and prioritize for receipt of a liver transplant.
Information and calculator

Child-Pugh Score

Child-Pugh Score
Purpose: To assess the severity of cirrhosis.
Information and calculator

Alcoholic Hepatitis Specific Tools

Maddrey's Discriminant Function for Alcoholic Hepatitis
Purpose: To predict prognosis in alcohol-related hepatitis and identify patients for treatment with steroids.
Information and calculator

Hepatic Encephalopathy Specific Tools

Clinical Hepatic Encephalopathy Staging Scale (CHESS)
By Dr. Christopher Rose (CRCHUM, University of Montreal) and Dr. Philip Wong (McGill University Health Centre), June 2016
Introductory letter available here. Scale sheet available here.

Hepatic Encephalopathy Symptom Tracker and Monitoring Tool (for Patients & Caregivers)
By Dr. Christopher Rose (CRCHUM, University of Montreal) and Dr. Philip Wong (McGill University Health Centre), June 2016
Download the symptom tracker here.

Hepatitis B Specific Tools

Reach-B Score
Purpose: To predict liver cancer risk in patients with chronic hepatitis B.
Find more information here.

Note:

The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.


Clinical Practice Guidelines

The following evidence-based clinical practice guidelines have been developed by experts and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventative aspects of care. The information links provided below have been reviewed by the Canadian Liver Foundation Medical Advisory Committee for relevance and scientific merit and have been posted with permission from the source.

Choosing Wisely Canada: Hepatology

Choosing Wisely Canada is a program to help clinicians and patients engage in conversations about unnecessary tests and treatments, and make smart and effective care choices.

Five Things Physicians and Patients Should Question
July 2017

Fatty Liver Disease

NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children:
Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)
Journal of Pediatric Gastroenterology and Nutrition, February 2017

The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease:
Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association 
Journal of Hepatology, June 2012 

Echinococcus multilocularis
Hemochromatosis

Diagnosis and Management of Hemochromatosis 
2011 Practice Guideline by the American Association for the Study of Liver Diseases
Journal of Hepatology, Vol. 54, No. 1, 2011

How I Treat Hemochromatosis 
Journal Blood, Vol. 116, No. 3, July 2010 (public access)

Hepatic Encephalopathy

Hepatic Encephalopathy in Chronic Liver Disease
2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
Journal of Hepatology, Vol. 60, Issue 2, Pages 715-735, August 2014

Clinical Hepatic Encephalopathy Staging Scale (CHESS)

By Dr. Christopher Rose (CRCHUM, University of Montreal) and Dr. Philip Wong (McGill University Health Centre), June 2016
Introductory letter available here.  

Hepatic Encephalopathy Symptom Tracker and Monitoring Tool (for Patients & Caregivers)
By Dr. Christopher Rose (CRCHUM, University of Montreal) and Dr. Philip Wong (McGill University Health Centre), June 2016

Hepatitis B

Caring for the Child with Chronic Hepatitis B Infection
By Constance O'Connor, MN and Simon Ling, MBChB
The Hospital for Sick Children, Toronto, Ontario, Canada, June 2014

Primary Care Management of Hepatitis B – Quick Reference
Public Health Agency of Canada, March 2013
Pour la version française, cliquez ici.

Management of Chronic Hepatitis B:
Consensus guidelines from the Canadian Association for the Study of the Liver 
Canadian Journal of Gastroenterology and Hepatology, December 2012

Management of Chronic Hepatitis B:
Canadian Association for the Study of the Liver Consensus Guidelines 
Canadian Journal of Gastroenterology and Hepatology, June 2007

Hepatitis C

Hepatitis C Screening & Testing Quick Reference Guide
Canadian Liver Foundation  (June 2016)
Pour la version en français, cliquez ici pour télécharger.

An Update on the Management of Chronic Hepatitis C 2015:
Consensus Guidelines from the Canadian Association for the Study of the Liver
Canadian Journal of Gastroenterology and Hepatology, Vol. 29, Issue 1: 19-34, January/February 2015

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group:
2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. 
Mark Hull, Stephen Shafran, Alex Wong, et al. Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2016, Article ID 4385643, 34 pages, 2016

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults
Canadian Journal of Infectious Diseases & Medical Microbiology, October 2014

An Update on the Management of Chronic Hepatitis C:
Consensus guidelines from the Canadian Association for the Study of the Liver 
Canadian Journal of Gastroenterology and Hepatology, June 2012

Management of Chronic Hepatitis C:
Consensus guidelines from the Canadian Association for the Study of the Liver 
Canadian Journal of Gastroenterology and Hepatology, June 2007

Hepatocellular Carcinoma (Liver Cancer)

Hepatocellular Carcinoma:
Consensus, controversies and future directions: A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting
Canadian Journal of Gastroenterology and Hepatology, Vol. 29, No. 4, May 2015

Focal Tumour Ablation in Ontario: Recommendations Report 2015
Focal Tumour Ablation Advisory Committee, Cancer Care Ontario / Action Cancer Ontario

Multidisciplinary Canadian Consensus Recommendations for the Management and Treatment of Hepatocellular Carcinoma
Journal of Current Oncology, Vol. 18, No. 5, 2011

Hepatology Clinical Textbook

Hepatology 2017: A Clinical Textbook 
By Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer.
To download free PDF or to buy a copy of the book, click here.

Liver Transplantation

Guidance on the Use of Increased Infectious Risk Donors for Organ Transplantation:
The CST/CNTRP Increased Risk Donor Working Group
Journal Transplantation, September 2014

Evaluation of the Pediatric Patient for Liver Transplantation:
2014 Practice Guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
Journal of Hepatology, Vol. 60, Issue 1, Pages 362-398, July 2014

Primary Biliary Cholangitis (formerly Primary Biliary Cirrhosis)

AASLD Practice Guidelines: Primary Biliary Cirrhosis
2009 Practice Guideline by the American Association for the Study of Liver Diseases
Journal of Hepatology, Vol. 50, No. 1, 2009

Note:

The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

 
Resources for You and Your Patients

The following tools and resources are available to further assist you in accessing information regarding prevention, diagnosis, treatment and care of various forms of liver disease.

If you would like general information about various forms of liver disease, or if you would like to offer your patients and their caregivers an opportunity to learn more about liver disease symptoms, treatments, tests, transplant and patient support programs, please visit our Patients & Caregivers section.

Additional professional education resources are offered below to help you effectively recognize, respond and resolve liver health issues in your practice. The information links provided have been reviewed by the Canadian Liver Foundation Medical Advisory Committee for relevance and scientific merit and have been posted with permission from the source:

Educational Videos & Slides

Biliary Atresia
"The Canadian Biliary Atresia Registry (CBAR) is a collaboration between the Canadian Pediatric Hepatology Research Group (CPHRG) and the Canadian Association of Pediatric Surgeons (CAPS), the two well-established networks in Canada involved with the care of children with biliary atresia."

To access more information for Physicians and Investigators, click here


Hepatitis B
International Hepatitis B Cure Workshop 2016
This one-day workshop will bring together global inter-disciplinary experts to enhance the field of hepatitis B research and to provide an interactive platform to achieve the goal of global hepatitis B cure. The meeting will include invited lectures, oral abstract presentations, poster view sessions, Q&A sessions, roundtable discussions and debates.

The slides and videos are now available online. Click here.

International Viral Hepatitis Elimination Meeting 2016
The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration

The slide and videos are now available online. Click here.


Hepatitis C
Hepatitis C Education National Needs Assessment
Canadian Liver Foundation and Canadian Association for the Study of the Liver, in partnership with the Canadian Association of Hepatology Nurses
(October 2015)

Assessment of the current knowledge of healthcare providers in the area of hepatitis C management, including screening and treatment using new antivirals, as well as the educational needs of healthcare providers at a national level.

Download the Hepatitis C Education National Needs Assessment here.

Educational grant provided by AbbVie Corporation.

Hepatitis C Screening and Testing
Morris Sherman, MD BCh PhD FRCP(C)
(November 2015)

 Click here to download.

6th Canadian Symposium on Hepatitis C Virus 2017
Delivering a Cure for Hepatitis C Infection: What are the Remaining Gaps?

The videos are now available online. Click here. 

5th Canadian Symposium on Hepatitis C Virus 2016
We're Not Done Yet - Remaining Challenges in Hepatitis C

The videos are now available online. Click here.
 
2nd Hepatitis Cure & Eradication Meeting 2015
The science of hepatitis research is revolutionizing our ability to cure and eliminate hepatitis. This workshop brought together global inter-disciplinary experts to provide a framework for how science can inform public policy to achieve the goal of global hepatitis eradication. 

The slides and videos are now available online. Click here

1st Hepatitis Cure & Eradication Meeting 2014
Leading experts from Canada, the Netherlands, China, Italy, USA, Australia and Germany lead this two-day translational and public health meeting with the objective to decrease the burden of disease, to simplify treatment and to cure and eradicate hepatitis. The Canadian Liver Foundation was please to provide academic endorsement of this educational event.

The slides and videos are now available online. Click here.

3rd Optimize Workshop: Using DAAS in Patients with Cirrhosis and Liver Recipients
This workshop focuses on current and emerging direct-acting individuals (DAAs) which promises to impact greatly the management of hepatitis C both prior to and after transplantation. Patients with cirrhosis, patients waiting on lists for liver transplantation, and liver recipients represent populations with a significant need for effective new therapies.

The slides and videos are now available online. Click here.

International Viral Hepatitis Elimination Meeting 2016 
The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration

The slide and videos are now available online. Click here.

Evolution and Revolution: Current Issues in HIV and Hepatitis C Virus Co-Infection 
Edited by: Marina B. Klein, MD MSc FRCP(C)
Posted with permission from: McGill University Health Centre
(May 2013, Updated January 2014)

Chapter 1 - HIV-Hepatitis C Virus Co-Infection: An Evolving Epidemic - Marina B. Klein, MD, MSc, FRCP(C) 
Chapter 2 - Management of HIV Infection in HIV/Hepatitis C Virus Co-Infected Patients - Mark Hull, MD, MHSc, FRCPC 
Chapter 3 - Management of Hepatitis C Virus Infection in HIV/Hepatitis C Virus Co-Infected Patients - Marie-Louise Vachon, MD, MSc 
Chapter 4 - Hepatitis C Virus Therapy: Direct Acting Antiviral Agents in Co-Infected Individuals - Curtis Cooper, MD, FRCPC 
Chapter 5 Drug Interactions with Directly Acting Antivirals for Hepatitis C Virus: An Overview & Challenges in HIV/Hepatitis C Virus Co-Infection - Alice Tseng, Pharm.D., FCSHP, AAHIVP 
Chapter 6 - Complicated Cases - David Fletcher, MD 
Chapter 7 - Future Trials of Hepatitis C Therapy in the HIV Co-Infected - Stephen D. Shafran, MD, FRCPC, FACP 
Chapter 8 - Hepatitis C Virus Infection in Marginalized Populations - Brian Conway, MD, FRCPC  
Chapter 9 - HIV/Hepatitis C Virus Co-Infection: Through the Eyes of a Co-Infected Hemophiliac - I.D. 
Chapters 1 - 9 Inclusive, Complete Slide Deck - Evolution and Revolution: Current Issues in HIV and Hepatitis C Virus Co-Infection 


Hepatic Encephalopathy
Hepatic Encephalopathy: Explore the Neuropsychiatric Consequences of Cirrhosis 
Prepared by: Dr. Christopher Rose, Dr. Hermant Shah, Dr. Puneeta Tandon and Dr. Philip Wong (June 2017)

A title that says Module 1 Introduction to cirrhosis and its complications
Click on the above image and save the Powerpoint Show to view the slides.

Module 1:
Chronic Liver Disease & Cirrhosis: An Introduction
Hepatic Encephalopathy: Overview
Hepatic Encephalopathy: Pathophysiology
Hepatic Encephalopathy: Clinical Classification
Covert Hepatic Encephalopathy: West Haven/Conn Score (0-1)
Covert Hepatic Encephalopathy: Testing

A title that says Module 2 Overt HE

Click on the above image and save the Powerpoint Show to view the slides.

Module 2:
Overt HE
Nonabsorbable Disaccharides: Lactulose
Dietary Modification: BCAA’s(Branched-Chain Amino Acids) Nutrition in cirrhosis

For a video version of the slides with voice-over narration, please click here.


Hepatocellular Carcinoma (Liver Cancer)
Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting: Consensus, Controversies and Future Directions

The slides and videos are now available online. Click here.


Liver Disease
Liver Disease in Canada: A Crisis in the Making 
(April 2013) 

Canadian Liver Foundation sounds the alarm on looming public health crisis

The Canadian Liver Foundation released "Liver Disease in Canada: A Crisis in the Making" - the first comprehensive report on liver disease in Canada. Findings include close to a 30 per cent increase in deaths from liver disease in the eight years from 2000-2007, with Ontario, Quebec, Alberta and British Columbia being hit hardest.

Click here to download.


Lysosomal Acid Lipase Deficiency (LALD)
Webinar : The Role of Pathology in Diagnosing Lysomal Acid Lipase Deficiency (LAL-D)
Presented by: Dr. Subrata Chakrabarti, Chair, Department of Pathology and Laboratory Medicine at Western University and Chief of Pathology and Laboratory Medicine at London Health Sciences Centre & St. Joseph's Health Care, London, Ontario, Canada.

Lysosomal Acid Lipase Deficiency (LAL-D) is an autosomal recessive lysosomal storage disorder [previously known as Wolman Disease (infants) and Cholesteryl Ester Storage Disease (children and adults)]. In pediatric and adult patients, nearly 50% progress to fibrosis, cirrhosis or liver transplant within 3 years of onset of symptoms.

For Healthcare Professionals: To request access to the webinar video, please click here to fill out the request form.

Hep C Resource Centre for Healthcare Professionals

To access the Canadian Liver Foundation's Hep C Resource Centre for Healthcare Professionals, click here.

HE Resource Centre for Healthcare Professionals

To access the HE Resource Centre for Healthcare Professionals, click here.

Physician Directories

Biliary Atresia Treating Physicians in Canada
"The Canadian Biliary Atresia Registry (CBAR) is a collaboration between the Canadian Pediatric Hepatology Research Group (CPHRG) and the Canadian Association of Pediatric Surgeons (CAPS), the two well-established networks in Canada involved with the care of children with biliary atresia." 

To access the Canadian Biliary Atresia Registry and Investigators, click here.


Hepatitis C Treating Physicians in Canada
Looking for physicians in your area who treat hepatitis C? The physicians in the searchable maps below have indicated that they treat hepatitis C. Please contact them to ask about patient referrals.

Maps available through the following links for:

Search Tips:
• Search by city, province, postal code, hospital, physician name, etc.
• If several physicians are in the same location, view multiple listings using the arrows at the bottom of a physician info box.
• Physician database will be updated as new information is received. Please check updated database for each new referral.

 

* If you would like the CLF to add, revise or remove your name from this database, please contact Karen Seto by email or phone at 1 (800) 563-5483 (Extension 4939).

Note
: The information provided in these directories has been provided by the physicians and have been posted with their permission. The Canadian Liver Foundation assumes no responsibility for any information or services provided by these physicians and the inclusion of their names on these directories does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

Note:

The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

 
Meetings & Conferences

With an estimated 1 in 4 Canadians who may be affected by liver disease, the Canadian Liver Foundation encourages all healthcare providers to seek opportunities for continuing medical education in the field of liver disease.

Educational meetings and conferences are available in Canada and around the world, addressing many forms of liver disease including non-alcoholic fatty liver disease, viral hepatitis, liver cancer, liver transplant, hepatic encephalopathy, pediatric liver disease, and many more.

Explore the conference lists and featured meetings below and find the educational events that will expand your knowledge on liver disease and help you improve liver health in your community.

2017 International Liver Meetings & Conferences

2018 International Liver Meetings & Conferences


Featured Upcoming Meetings

International Hepatitis B Cure Workshop
The logo for the International HBV Cure Forum 2017

This one-day workshop will bring together global inter-disciplinary experts to enhance the field of hepatitis B research and to provide an interactive platform to achieve the goal of global hepatitis B cure. The meeting will include invited lectures, oral abstract presentations, poster viewing sessions, Q&A sessions, roundtable discussions and debates. 

CLF partners, volunteers and supporters can receive 50% off workshop registration fees. Please contact Karen Seto to get your CLF discount code for registration.

Date: October 18, 2017
Location: Toronto, Ontario, Canada
Website & Registration: Click here.

International Viral Hepatitis Elimination Meeting 2017
The logo for the International Viral Hepatitis Elimination Meeting 2017

The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration

CLF partners, volunteers and supporters can receive 25% off workshop registration fees. Please contact Karen Seto to get your CLF discount code for registration.

Date: November 17 - 18, 2017
Location: Amsterdam, The Netherlands
Program Information: Click here.
Website & Registration: Click here.

If you would like the CLF to add or revise your meeting or conference information, please contact Karen Seto by email or phone at 1 (800) 563-5483 (Extension 4939).

Note: The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

We want to hear from the medical community. Input from you helps us to identify professional education programs and resources which meet the needs of your patients and your community. If you would like information or education in a particular area (i.e.: paediatric, liver health/prevention, etc.) or type of liver disease (i.e.: fatty liver disease, hepatitis, liver cancer, etc.), please contact Karen Seto by email or phone at 1 (800) 563-5483 (Extension 4939). 

Back to top